Condition: Adenocarcinoma · Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
This study primarily evaluates the efficacy and safety of the LM-302 plus tislelizumab regimen versus tislelizumab plus chemotherapy in the treatment of previously untreated locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma patients with CLDN18.2 positivity.
This description comes directly from the study's public registry record.
Lin Shen, Doctor · 13911219511 · dctorshenlin@sina.cn
Jin Li, Doctor · 13761222111 · lijin@csco.org.cn
Always discuss trial participation with your own doctor first.
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Anhui Provincial Hospital (The First Affiliated Hospital of China University of Science and Technology) | Hefei, Anhui, China | Not Yet Recruiting |
| The Second Hospital Of Anhui Medical University | Hefei, Anhui, China | Not Yet Recruiting |
| The First Affiliated Hospital Of Wannan Medical College | Wuhu, Anhui, China | Not Yet Recruiting |
| Beijing Friendship Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Lu He Hospital ,Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Gaobo Hospital Co., Ltd. | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Tsinghua changgung Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Chongqing University Three Gorges Hospital | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
+ 94 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07385703